Orchestra Competitors
| OBIO Stock | 3.49 0.24 6.43% |
Orchestra BioMed vs Avalo Therapeutics Correlation
Very weak diversification
The correlation between Orchestra BioMed Holdings and AVTX is 0.4 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Orchestra BioMed Holdings and AVTX in the same portfolio, assuming nothing else is changed.
Moving against Orchestra Stock
| 0.48 | ALKS | Alkermes Plc | PairCorr |
| 0.47 | APLT | Applied Therapeutics | PairCorr |
| 0.42 | RNAZ | Transcode Therapeutics | PairCorr |
| 0.36 | ACLX | Arcellx | PairCorr |
| 0.32 | RANI | Rani Therapeutics | PairCorr |
Orchestra BioMed Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Orchestra BioMed and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Orchestra and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Orchestra BioMed Holdings does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Orchestra Stock performing well and Orchestra BioMed Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Orchestra BioMed's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PRLD | 9.32 | 1.96 | 0.13 | (0.92) | 11.51 | 16.44 | 206.09 | |||
| IVA | 4.14 | 0.18 | 0.02 | 0.31 | 6.86 | 10.82 | 34.91 | |||
| CRBU | 3.02 | (0.87) | 0.00 | (0.24) | 0.00 | 6.86 | 20.16 | |||
| ENTA | 2.45 | 0.34 | 0.10 | 2.03 | 2.61 | 5.67 | 15.79 | |||
| IVVD | 4.97 | (0.03) | 0.00 | 6.41 | 0.00 | 11.11 | 46.37 | |||
| PYXS | 6.12 | (0.73) | 0.00 | (0.38) | 0.00 | 17.05 | 70.66 | |||
| TARA | 4.04 | 0.63 | 0.11 | 1.56 | 4.79 | 11.78 | 39.96 | |||
| TNYA | 4.87 | (1.00) | 0.00 | (0.23) | 0.00 | 10.57 | 51.79 | |||
| EPRX | 3.04 | 0.69 | 0.20 | 1.28 | 2.86 | 6.98 | 24.61 | |||
| AVTX | 3.41 | (0.14) | 0.00 | (0.55) | 0.00 | 6.64 | 23.40 |
Cross Equities Net Income Analysis
Compare Orchestra BioMed Holdings and related stocks such as Prelude Therapeutics, Inventiva Sa, and Caribou Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRLD | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (27.6 M) | (56.9 M) | (110.8 M) | (107.3 M) | (121.8 M) | (127.2 M) | (114.5 M) | (120.2 M) |
| IVA | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.5 M) | (8.8 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (31.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (102.1 M) | (149.1 M) | (134.2 M) | (127.5 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| IVVD | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (226.8 M) | (241.3 M) | (198.6 M) | (169.9 M) | (152.9 M) | (160.6 M) |
| PYXS | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.8 M) | (76 M) | (118 M) | (73.8 M) | (77.3 M) | (69.6 M) | (73.1 M) |
| TARA | (8 M) | (8 M) | (8 M) | (7.9 M) | (3.3 M) | (21.4 M) | (28.5 M) | (30 M) | (25.4 M) | (15 M) | (34 M) | (47.3 M) | (66 M) | (40.4 M) | (44.6 M) | (40.1 M) | (42.1 M) |
| TNYA | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (38.4 M) | (69.7 M) | (123.7 M) | (124.1 M) | (111.1 M) | (100 M) | (105 M) |
| EPRX | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (13.2 M) | (7.4 M) | (4 M) | (18 M) | (18.5 M) | (28.2 M) | (36.7 M) | (33 M) | (31.4 M) |
| AVTX | (10.5 M) | (10.5 M) | (10.5 M) | (13 M) | (16.1 M) | (10.5 M) | (16.5 M) | 11.9 M | (40.1 M) | (16.1 M) | (63.5 M) | (84.4 M) | (41.7 M) | (31.5 M) | (35.1 M) | (31.6 M) | (33.2 M) |
Orchestra BioMed Holdings and related stocks such as Prelude Therapeutics, Inventiva Sa, and Caribou Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Orchestra BioMed Holdings financial statement analysis. It represents the amount of money remaining after all of Orchestra BioMed Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Orchestra BioMed Competitive Analysis
The better you understand Orchestra BioMed competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Orchestra BioMed's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Orchestra BioMed's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Orchestra BioMed Competition Performance Charts
Five steps to successful analysis of Orchestra BioMed Competition
Orchestra BioMed's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Orchestra BioMed Holdings in relation to its competition. Orchestra BioMed's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Orchestra BioMed in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Orchestra BioMed's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Orchestra BioMed Holdings, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Orchestra BioMed position
In addition to having Orchestra BioMed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 548 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Orchestra BioMed Correlation with its peers. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Biotechnology sector continue expanding? Could Orchestra diversify its offerings? Factors like these will boost the valuation of Orchestra BioMed. Anticipated expansion of Orchestra directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Orchestra BioMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.80) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Orchestra BioMed Holdings's market price often diverges from its book value, the accounting figure shown on Orchestra's balance sheet. Smart investors calculate Orchestra BioMed's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Orchestra BioMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Orchestra BioMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Orchestra BioMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.